To include your compound in the COVID-19 Resource Center, submit it here.

Gelesis reports mixed data for hydrogel weight loss product

Gelesis Inc. (Boston, Mass.) said lead candidate Gelesis100 met 1 of 2 co-primary endpoints in the pivotal GLOW weight loss trial. COO David Pass told

Read the full 258 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE